Keytruda (pembrolizumab) is a humanized monoclonal antibody that targets the PD-1 receptor, blocking its interaction with PD-L1 and PD-L2. Approved across 20+ indications, it is the world’s best-selling pharmaceutical product and the cornerstone of Merck’s oncology franchise.
Keytruda binds to the PD-1 receptor on T cells, preventing interaction with PD-L1/PD-L2 on tumor cells. This releases the immune system "brakes," allowing T cells to recognize and attack cancer cells across a broad range of tumor types.
Annual revenue trajectory
Revenue of competing drugs in the same class
10 indications
All approved therapeutic uses
Keytruda dominates the checkpoint inhibitor market with ~60% share of the PD-1/PD-L1 class. Its broad label across 20+ indications, strong efficacy, and 1,600+ clinical trials create a formidable competitive moat.
Projected to reach $30B+ by 2026 before biosimilar competition in 2028. Merck pursuing subcutaneous formulation and novel combinations to extend the franchise.
| Drug | Company | Revenue |
|---|---|---|
| Opdivo (nivolumab) | Bristol-Myers Squibb | $9.0B |
| Tecentriq (atezolizumab) | Roche | $4.0B |
| Imfinzi (durvalumab) | AstraZeneca | $4.2B |
| Libtayo (cemiplimab) | Sanofi/Regeneron | $0.8B |
| Yervoy (ipilimumab) | BMS | $2.2B |
Revenue figures from company annual reports (FY2023). Clinical trial data from ClinicalTrials.gov. Competitive intelligence from Evaluate Pharma World Preview 2024 and IQVIA MIDAS. Market analysis by Medifirm Intelledge Global.